- Home
- ZH vs NGNE Comparison
ZH vs NGNE Comparison
Compare ZH & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- NGNE
- Stock Information
- Founded
- ZH 2011
- NGNE 2003
- Country
- ZH China
- NGNE United States
- Employees
- ZH N/A
- NGNE N/A
- Industry
- ZH Business Services
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- NGNE Health Care
- Exchange
- ZH Nasdaq
- NGNE Nasdaq
- Market Cap
- ZH 352.6M
- NGNE 325.3M
- IPO Year
- ZH 2021
- NGNE N/A
- Fundamental
- Price
- ZH $4.51
- NGNE $22.72
- Analyst Decision
- ZH Strong Buy
- NGNE Strong Buy
- Analyst Count
- ZH 1
- NGNE 7
- Target Price
- ZH $4.70
- NGNE $41.86
- AVG Volume (30 Days)
- ZH 318.7K
- NGNE 216.3K
- Earning Date
- ZH 08-21-2025
- NGNE 08-08-2025
- Dividend Yield
- ZH N/A
- NGNE N/A
- EPS Growth
- ZH N/A
- NGNE N/A
- EPS
- ZH N/A
- NGNE N/A
- Revenue
- ZH $464,095,225.00
- NGNE $925,000.00
- Revenue This Year
- ZH N/A
- NGNE N/A
- Revenue Next Year
- ZH $7.46
- NGNE N/A
- P/E Ratio
- ZH N/A
- NGNE N/A
- Revenue Growth
- ZH N/A
- NGNE N/A
- 52 Week Low
- ZH $3.01
- NGNE $6.88
- 52 Week High
- ZH $6.32
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- ZH 52.60
- NGNE 60.64
- Support Level
- ZH $4.58
- NGNE $20.80
- Resistance Level
- ZH $4.95
- NGNE $23.88
- Average True Range (ATR)
- ZH 0.19
- NGNE 1.44
- MACD
- ZH -0.02
- NGNE 0.09
- Stochastic Oscillator
- ZH 10.20
- NGNE 72.83
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.